Kincell Bio, a leader in cell therapy development and manufacturing, has appointed Stewart McNaull, PhD, as Chief Commercial Officer (CCO).
 
With extensive experience in the advance therapies Contract Development and Manufacturing Organization (CDMO) space and a robust technical background, Dr. McNaull will play a pivotal role in steering Kincell Bio’s growth trajectory and enhancing its commitment to serving cell therapy innovators and the patients who ultimately benefit from these groundbreaking therapies.

Experience 

McNaull joins Kincell Bio with 25 years of experience in the biopharmaceutical industry, having held key commercial leadership positions at Wheeler Bio, Resilience, KBI, Fujifilm and Bayer. His understanding of the CDMO landscape and ability to craft technical and business solutions that address clients’ needs position him to deliver high-quality, innovative solutions for clients.
 
“I am thrilled to join the highly talented team to advance Kincell’s cell therapy service offerings,” said McNaull. “It is refreshing to return to the cell therapy space where my knowledge of CMC development can help design technical and business solutions that uniquely advance our clients’ products to the clinic.”
 
“Stewart’s extensive background in both commercial leadership and technical operations makes him an invaluable addition to our team,” said Bruce Thompson, PhD, CEO of Kincell Bio. “As we continue to expand our capabilities and enhance our service offerings, Stewart’s insights and industry relationships will be instrumental in fostering partnerships that drive success for our clients and improve outcomes for patients.”